Search Result

Results for "

6 fgfr Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (151) Akt (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (19) Aurora Kinase (3) Autophagy (11) Bcr-Abl (2) c-Fms (6) c-Kit (18) c-Met/HGFR (2) CDK (3) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) Discoidin Domain Receptor (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) EGFR (5) Endogenous Metabolite (3) FAK (1) FLT3 (12) GSK-3 (1) HDAC (1) Insulin Receptor (1) Isotope-Labeled Compounds (5) JAK (1) LIM Kinase (LIMK) (1) MAP3K (1) Nucleoside Antimetabolite/Analog (1) PDGFR (42) PROTACs (1) Raf (2) Reactive Oxygen Species (1) RET (6) Ribosomal S6 Kinase (RSK) (1) Src (16) Syk (1) Trk Receptor (1) VEGFR (53)
By Research Areas:	Cancer (162) Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (1)

By Targets:

FGFR (151)

Akt (1)

AMPK (1)

Anaplastic lymphoma kinase (ALK) (2)

Apoptosis (19)

Aurora Kinase (3)

Autophagy (11)

Bcr-Abl (2)

c-Fms (6)

c-Kit (18)

c-Met/HGFR (2)

CDK (3)

Checkpoint Kinase (Chk) (1)

Cytochrome P450 (1)

Discoidin Domain Receptor (1)

Drug Metabolite (3)

Drug-Linker Conjugates for ADC (1)

EGFR (5)

Endogenous Metabolite (3)

FAK (1)

FLT3 (12)

GSK-3 (1)

HDAC (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (5)

JAK (1)

LIM Kinase (LIMK) (1)

MAP3K (1)

Nucleoside Antimetabolite/Analog (1)

PDGFR (42)

PROTACs (1)

Raf (2)

Reactive Oxygen Species (1)

RET (6)

Ribosomal S6 Kinase (RSK) (1)

Src (16)

Syk (1)

Trk Receptor (1)

VEGFR (53)

By Research Areas:

Cancer (162)

Cardiovascular Disease (4)

Infection (1)

Inflammation/Immunology (6)

Metabolic Disease (1)

Neurological Disease (1)

172

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112412

PDGFR Tyrosine Kinase Inhibitor III PDGF Receptor Tyrosine Kinase Inhibitor III	PDGFR	Neurological Disease
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .

HY-156790

FGFR3-IN-6

FGFR Cancer

FGFR3-IN-6 is a potent and selective FGFR3 inhibitor with IC₅₀ value less than 350 nM. FGFR3-IN-6 can be used in research of cancer .
HY-156791

FGFR3-IN-7

FGFR Cancer

FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC₅₀ value less than 350 nM. FGFR3-IN-7 can be used in research of cancer .

FGFR3-IN-6	FGFR	Cancer
FGFR3-IN-6 is a potent and selective FGFR3 inhibitor with IC₅₀ value less than 350 nM. FGFR3-IN-6 can be used in research of cancer .

FGFR3-IN-7	FGFR	Cancer
FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC₅₀ value less than 350 nM. FGFR3-IN-7 can be used in research of cancer .

HY-163273

FGFR4-IN-17	FGFR	Cancer
FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a *FGFR* inhibitor with IC₅₀ values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .

HY-161326

CXF-007

FGFR Cancer

CXF-007 is a potent and specific FGFR4 inhibitor with a IC₅₀ value of 7 nM. CXF-007 has antitumor activity .

CXF-007	FGFR	Cancer
CXF-007 is a potent and specific *FGFR4* inhibitor with a IC₅₀ value of 7 nM. CXF-007 has antitumor activity .

HY-150026

Multi-kinase-IN-2	VEGFR PDGFR FGFR c-Kit Akt Src Apoptosis	Cancer
Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and *FGFR-1, as well as LYN* and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity .

HY-146541

FGFR4-IN-10	FGFR	Cancer
FGFR4-IN-10 (compound 5a) is a potent and selective *FGFR4* inhibitor with an IC₅₀ value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .

HY-147515

FGFR4-IN-11	FGFR	Cancer
FGFR4-IN-11 (Compound 30) is a potent, selective, covalent *FGFR4* inhibitor with an IC₅₀ of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .

HY-101466

E7090

FGFR Cancer

E7090 is an orally available, potent, and selective FGFR inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively .

E7090	FGFR	Cancer
E7090 is an orally available, potent, and selective *FGFR* inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for *FGFR1/FGFR2/FGFR3/FGFR4*, respectively .

HY-151903S

FGFR2/3-IN-1	FGFR	Cancer
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively[1].

HY-149487

FGFR1 inhibitor-8	FGFR	Cancer
FGFR1 inhibitor-8 (Compound 9) is a *FGFR1* inhibitor (IC₅₀s: 0.5 nM). FGFR1 inhibitor-8 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-8 has anticancer activity .

HY-149488

FGFR1 inhibitor-9	FGFR	Cancer
FGFR1 inhibitor-9 (Compound 7) is an *FGFR1* inhibitor (IC₅₀s: 0.85 nM). FGFR1 inhibitor-9 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-9 has anticancer activity .

HY-148779

FGFR3-IN-5	FGFR	Cancer
FGFR3-IN-5 is a potent and selective *FGFR3* inhibitor with IC₅₀ values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .

HY-156019

FGFR1 inhibitor-10	FGFR	Cancer
FGFR1 inhibitor-10 (Compound 4i) is an *FGFR1* inhibitor (IC₅₀: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .

HY-145231

FGFR2-IN-2

FGFR Cancer

FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC₅₀s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .

FGFR2-IN-2	FGFR	Cancer
FGFR2-IN-2 (Compound 38) is a selective *FGFR2* inhibitor with IC₅₀s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .

HY-155028

FGFR-IN-11	FGFR	Cancer
FGFR-IN-11 (compound I-5) is an orally active and covalent *FGFR* inhibitor with IC₅₀ values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (FGFR4), respectively. FGFR-IN-11 inhibits multiple cancer cell proliferation with nanomolar activity. FGFR-IN-11 inhibits tumor growth significantly in xenograft mice models .

HY-144759

FGFR4-IN-9

FGFR Cancer

FGFR4-IN-9 (Compound 6O) is a selective FGFR4 inhibitor with an IC₅₀ of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .
HY-148778

FGFR3-IN-4

FGFR Cancer

FGFR3-IN-4 is a selective FGFR3 inhibitor, with an IC₅₀ value of less than 50 nM. FGFR3-IN-4 is at least 10 fold more selective for FGFR3 than for FGFR1 .
HY-18602

FIIN-2

FGFR Cancer

FIIN-2 is an irreversible inhibitor of FGFR with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
HY-145043

FGFR-IN-1

FGFR Cancer

FGFR-IN-1 is a potent FGFR inhibitor with an IC₅₀ of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) .
HY-145230

FGFR2-IN-1

FGFR Others

FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC₅₀ of 140 nM.
HY-156704

FGFR4-IN-16

FGFR Cancer

FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research .
HY-18603

FIIN-3

EGFR FGFR Cancer

FIIN-3 is an irreversible inhibitor of FGFR with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
HY-158010

FGFR3-IN-8

FGFR Cancer

FGFR3-IN-8 (example91) is a selective FGFR3 inhibitor .
HY-158011

FGFR3-IN-9

FGFR Cancer

FGFR3-IN-9 (example27) is a selective FGFR3 inhibitor .
HY-13304

LY2874455

3 Publications Verification

FGFR Cancer

LY2874455 is a pan-FGFR inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

FGFR4-IN-9	FGFR	Cancer
FGFR4-IN-9 (Compound 6O) is a selective *FGFR4* inhibitor with an IC₅₀ of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .

FGFR3-IN-4	FGFR	Cancer
FGFR3-IN-4 is a selective *FGFR3* inhibitor, with an IC₅₀ value of less than 50 nM. FGFR3-IN-4 is at least 10 fold more selective for FGFR3 than for FGFR1 .

FIIN-2	FGFR	Cancer
FIIN-2 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

FGFR-IN-1	FGFR	Cancer
FGFR-IN-1 is a potent *FGFR* inhibitor with an IC₅₀ of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) .

FGFR2-IN-1	FGFR	Others
FGFR2-IN-1 is a selective *FGFR2* inhibitor with an IC₅₀ of 140 nM.

FGFR4-IN-16	FGFR	Cancer
FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of *FGFR-4* for cancer research .

FIIN-3	EGFR FGFR	Cancer
FIIN-3 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

FGFR3-IN-8	FGFR	Cancer
FGFR3-IN-8 (example91) is a selective *FGFR3* inhibitor .

FGFR3-IN-9	FGFR	Cancer
FGFR3-IN-9 (example27) is a selective *FGFR3* inhibitor .

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for *FGFR1, FGFR2, FGFR3, FGFR4*, respectively.

HY-142921

FGFR-IN-2	FGFR	Cancer
FGFR-IN-2 (compound 1) is a potent *FGFR* inhibitor with IC₅₀s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research .

HY-19957

Zoligratinib 2 Publications Verification Debio 1347; CH5183284	FGFR	Cancer
Zoligratinib (Debio 1347) is an orally available and selective *FGFR* inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-115902

FGFR4-IN-7	FGFR Apoptosis	Cancer
FGFR4-IN-7 (Compound C3) is a covalent reversible *FGFR4* inhibitor with an IC₅₀ value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .

HY-101544

ARQ 069	FGFR	Cancer
ARQ 069, an analog of ARQ 523, inhibits *FGFR* in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC₅₀s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC₅₀s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner .

HY-152104

FGFR-IN-9	FGFR	Cancer
FGFR-IN-9 (Compound 19) is a potent, reversible and orally active *FGFR* inhibitor with an IC₅₀ of 17.1, 29.6, 30.7, 46.7 and 64.3 nM against FGFR4 ^WT, FGFR3, FGFR4 ^V550L, FGFR2 and FGFR1, respectively .

HY-100019

Rogaratinib 5 Publications Verification BAY1163877	FGFR	Cancer
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively .

HY-149512

FGFR1/VEGFR2-IN-1

FGFR VEGFR Cancer

FGFR1/VEGFR2-IN-1 (compound 2b) is an FGFR1/VEGFR2 inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .

FGFR1/VEGFR2-IN-1	FGFR VEGFR	Cancer
FGFR1/VEGFR2-IN-1 (compound 2b) is an *FGFR1/VEGFR2* inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .

HY-13330

Fexagratinib 15+ Cited Publications AZD4547; ADSK091	FGFR	Cancer
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-13311A

Infigratinib phosphate 20+ Cited Publications BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the *FGFR* family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-147714

FGFR3-IN-2	FGFR VEGFR	Cancer
FGFR3-IN-2 (compound 18b) is a potent and selective *FGFR3* inhibitor, with IC₅₀s of 4.1 nM and 570 nM for *FGFR3* and VEGFR2, respectively. FGFR3-IN-2 can be used for the research of bladder cancer .

HY-147793

FGFR4-IN-12	FGFR	Cancer
FGFR4-IN-12 (Compound A34) is a potent inhibitor of *FGFR4. FGFR4-IN-12 exhibits improved FGFR4 inhibitory capability and selectivity and excellent anti-proliferative activities against FGFR4-dependent HCC cell lines. FGFR4-IN-12 has the potential for the research of cancer diseases . FGFR*4-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147713

FGFR3-IN-1	FGFR	Cancer
FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC₅₀s of 40 nM, 5.1 nM, and 12 nM for *FGFR1, 2, and 3, respectively. FGFR*3-IN-1 can be used for the research of bladder cancer .

HY-162283

FGFR4-IN-18

FGFR Cancer

FGFR4-IN-18 (compound 8z) is an inhibitor of FGFR4 and can be used in cancer research .

FGFR4-IN-18	FGFR	Cancer
FGFR4-IN-18 (compound 8z) is an inhibitor of FGFR4 and can be used in cancer research .

HY-13311

Infigratinib 20+ Cited Publications BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-13311S

Infigratinib-d3 BGJ-398-d₃; NVP-BGJ398-d₃	FGFR	Cancer
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-131704

FGFR4-IN-5	FGFR	Cancer
FGFR4-IN-5 is a potent and selective covalent *FGFR4* inhibitor with an IC₅₀ of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .

HY-147715

FGFR3-IN-3	FGFR	Cancer
FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC₅₀s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for *FGFR1, 2, 3, and 4, respectively. FGFR*3-IN-3 can be used for the research of bladder cancer .

HY-155046

FGFR4-IN-14	FGFR	Cancer
FGFR4-IN-14 (Compound 27i) is a *FGFR4* inhibitor (IC₅₀: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC₅₀s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .

HY-101768

PRN1371 1 Publications Verification	FGFR c-Fms	Cancer
PRN1371 is a highly selective and potent *FGFR1-4* and CSF1R inhibitor with IC₅₀s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .

HY-109099

Pemigatinib 5+ Cited Publications INCB054828	FGFR	Cancer
Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-143272

FGFR1 inhibitor-6	FGFR	Cancer
FGFR1 inhibitor-6 is a potent *FGFR1* inhibitor with an IC₅₀ value of 16.31 nM. FGFR1 inhibitor-6 shows cytotoxic activities. FGFR1 inhibitor-6 induces apoptosis and cell cycle arrest at pre-G1 and G2/M phase .

HY-101466A

E7090 succinate	FGFR	Cancer
E7090 succinate is an orally available, selective and potent inhibitor of **FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC₅₀** values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively .

HY-145836

FGFR4-IN-8	FGFR	Cancer
FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant *FGFR4. FGFR4-IN-8 exhibits excellent potency against FGFR4, FGFR4 ^V550L, FGFR4 ^V550M and FGFR4 ^C552S with IC₅₀s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC₅₀ value of 29 nM. FGFR*4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model .

HY-129181

FGFR4-IN-4

FGFR Cancer

FGFR4-IN-4 (compound 693) is a FGFR4 inhibitor with anti-tumor activity, extracted from patent WO2018113584A1 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0060A

Ferulic acid sodium 5 Publications Verification Coniferic acid sodium	Structural Classification Monophenols other families Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Endogenous metabolite Disease Research Fields Cancer	FGFR Endogenous Metabolite Reactive Oxygen Species
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060

Ferulic acid 5 Publications Verification Coniferic acid	Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Sunscreen Phenols Phenylpropanoids Cosmetic Research Disease Research Fields Cancer	FGFR Endogenous Metabolite
Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N7715

Ferulic acid acyl-β-D-glucoside Ferulic acid glucoside	Monophenols Classification of Application Fields Simple Phenylpropanols Source classification Other Diseases Rosaceae Phenols Phenylpropanoids Plants Aruncus sylvester Kostel. Disease Research Fields	Drug Metabolite
Ferulic acid acyl-β-D-glucoside is a metabolite of Ferulic Acid (HY-N0060) . Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively .

HY-N0183

Formononetin Maximum Cited Publications 9 Publications Verification Biochanin B; Flavosil; Formononetol	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Flavonoids other families Sunscreen Leguminosae Cosmetic Research Disease Research Fields Glycyrrhiza uralensis Fisch. Isoflavones	FGFR Apoptosis
Formononetin is a potent *FGFR2* inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-N9507

Picrasidine Q	Alkaloids other families Classification of Application Fields Source classification Quinoline Alkaloids Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis FGFR
Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell apoptosis and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits *FGFR2* kinase activity .

Cat. No.	Product Name	Chemical Structure

HY-151903S

FGFR2/3-IN-1
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively[1].

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-N0060S1

Ferulic acid-13C3
Ferulic acid- ¹³C₃ is the ¹³C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks